Clinical Trial Update: Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study evaluating nintedanib (BIBF 1120) in Japanese patients with hepatocellular carcinoma has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Nintedanib (nintedanib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Hepatocellular | Phase 1 | Status: COMPLETED | Results posted: 2015-12-22